Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Thu, 26th Nov 2009 14:45

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m."Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a gradual increase in the release of new orders in the months ahead," said chairman Chris Geoghegan."Tooling order books have increased in September and October and with leading indicators now generally more encouraging, we are cautiously optimistic of seeing further order strengthening over the second half."Gold and copper explorer Bezant lost £1.77m in the year ended 30 June 2009 due to its exploration activities in the Philippines and Tanzania.Executive chairman Gerry Nealon says Bezant's flagship Mankayan project in the Philippines has the potential to become a world class mine. News on future plans are expected early next yearPre-tax profit fell to £189,000 at Tangent Communications in the six months to 31 August, down from £500,000 in 2008, although the direct marketing firm says the outlook for the rest of the year is in line with management's expectations."The increased cost base from our recent acquisitions had a negative impact on the overall profitability, although we expect this investment in skills to deliver future growth in higher margin parts of the business," said the group.Stem cell developer ReNeuron narrowed losses from £3m to £2m in the year to September and said it has secured a two-year equity funding facility up to £5m from its joint broker, Matrix Corporate Capital.The AIM-listed firm said it remains confident of meeting the remaining requirements for its pioneering ReN001 therapy for stroke to allow initiation of a first-in-man clinical trial early next year.Alexon Group, the ladies clothing retailer, reports total sales for the 16 weeks to 21 November dropped 14% on a like for like basis.The firm blamed a 16.9% slump in sales for the first 8 weeks of the period on its decision to make fewer summer reductions, although they fell just 8.7% in the final 8 weeks. "Looking ahead, the board anticipates that the current price competitive environment will continue through the critical Christmas trading period and into the January sales. This is likely to adversely affect margins but the company's financial position remains secure," it said.
More News
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more
5 Jul 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

Read more
19 Apr 2018 13:17

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Read more
3 Apr 2018 13:29

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

Read more
26 Mar 2018 15:53

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

Read more
5 Dec 2016 11:06

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Read more
4 Dec 2016 14:45

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

Read more
6 Sep 2016 11:38

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

Read more
7 Jul 2016 09:37

ReNeuron Annual Loss Widens As Product Trials Ramp Up

Read more
4 Jul 2016 15:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Jun 2016 07:58

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

Read more
9 Jun 2016 08:55

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

Read more
8 Jun 2016 08:36

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

Read more
15 Mar 2016 09:52

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.